Last checked at 4 Nov 2022 16:16
4 November 2022
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Grant of Options and PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that on 3 November 2022, options ("Options") to subscribe for an aggregate of 196,809 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted to Adam Hill (Chief Executive Officer), Matthew Hall (Chief Financial Officer) and Ron Kirschner (General Counsel & Company Secretary) as follows:
Name | Position | No. of Options Awarded | Exercise Price per Share |
Adam Hill | Chief Executive Officer | 125,000 | £0.50 |
Matthew Hall | Chief Financial Officer | 30,000 | £0.50 |
Ron Kirschner | General Counsel & Company Secretary | 30,000 | £0.50
|
The Options have been granted under the 2016 Share Option Plan, have an exercise price of £0.50, being the closing price of Ordinary Shares in Oncimmune Holdings plc on 2 November 2022, and vest annually in five equal parts from the date of grant until the fifth anniversary of grant.
Following this grant, each of Adam Hill, Matthew Hall and Ron Kirschner hold the following interests in the Company:
Name | Number of Ordinary Shares currently held | Number of Options held post grant |
Adam Hill | 73,872 | 3,615,862 |
Matthew Hall | 11,935 | 809,554 |
Ron Kirschner | 1,652 | 556,738 |
This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation and serves as notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| 1. Adam Hill 2. Matthew Hall 3. Ron Kirschner | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| 1. Chief Executive Officer 2. Chief Financial Officer 3. General Counsel & Company Secretary | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Oncimmune Holdings plc | |||
b)
| LEI
| 213800HCYIWT6YPI1I02 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each
| |||
Identification code | ISIN: GB00BYQ94H38 | ||||
b)
| Nature of the transaction
| Grant of options | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
1. £0.50 | 125,000 | ||||
2. £0.50 | 30,000 | ||||
3. £0.50 | 30,000 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | N/A - single transaction | ||||
- Price | |||||
e)
| Date of the transaction
| 3 November 2022 | |||
f)
| Place of the transaction
| Outside a trading venue | |||
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Erland Sternby
+44 (0)20 3705 9321
Media enquiries:
Freelands Finance
John Goold
IR@oncimmune.com